ClinicalTrials.Veeva

Menu
M

Mid Hudson Medical Research, PLLC | New Windsor, NY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Bococizumab
Simufilam
MK-0616
KarXT
ARO-APOC3
SUVN-502
MK-2214-004
Naltrexone Hydrochloride
MK-2214
LY3437943

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 51 total trials
Locations recently updated

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). A...

Enrolling
Early Alzheimer's Disease
Biological: MK-2214
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disea...

Enrolling
Alzheimer Disease
Drug: Xanomeline Enteric Capsule
Drug: Xanomeline/Trospium Chloride Capsule

This is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 67...

Active, not recruiting
Alzheimer Disease 6
Cognitive Impairment
Device: Spectris™ AD - Active
Device: Spectris™ AD - Sham
Locations recently updated

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide
Locations recently updated

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with mod...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: KarXT

The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their...

Active, not recruiting
Distal Sensory Polyneuropathy
Neuropathic Pain
Drug: Placebo
Drug: LY3848575

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Active, not recruiting
Arteriosclerosis
Hypercholesterolaemia
Drug: Enlicitide Decanoate
Drug: Placebo

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic per...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: Placebo (matched to SUZ)
Drug: Suzetrigine

This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study.Participants who complete...

Invitation-only
Alzheimer Disease
AD
Device: Sensory Stimulation System (GS120) - Active

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatmen...

Enrolling
Agitation
Alzheimer's Type Dementia
Drug: Masupirdine 100 mg
Drug: Placebo

This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participan...

Enrolling
Alzheimer Disease
Agitation
Drug: Placebo
Drug: BMS-986368

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Pfizer logo
Lilly logo
Sanofi logo
Arrowhead Pharmaceuticals logo
C
Cognito Therapeutics logo
Exact Sciences Corporation logo
Novartis logo
Novo Nordisk logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems